Skip to content

To know the efficacy of two unani formulations in deranged lipid levels

A Randomized Open Study to Compare the Efficacy of Two Unani Formulations in the Management of Dyslipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045383
Enrollment
60
Registered
2022-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Safoof-e- kundur: drug will be given 6 grams orally twice a day for 90 days ater food Control Intervention1: Lipotab: Drug will be gien 2 tab at bed time orally for 90 days

Sponsors

Department of moalajat Ajmal khan Tibbiya college Aligarh Muslim university Aligarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A) Patients between 30-60 years of age, both male and female B) Patient ready to participate in the study and ready to follow the instructions Subjective criteria: a) Increased body weight b) Dyspnea on exertion c) Fatigue d) Xanthelasma e) Xanthoma f) Corneal arcus Objective criteria Lipid profile: Serum cholesterol: 200-300mg/dl Serum triglycerides: 200-300mg/dl Serum HDL: 30-50 mg/dl Serum LDL: 100-150 mg/dl Serum VLDL: 30-50 mg/dl BMI: 25-30kg/m2

Exclusion criteria

Exclusion criteria: Exclusion criteria: A) Pregnacy and lactation B) Diabetic patient having HBAlc >8 % and FBS >250 mg /dl C) Diabetes mellitus with complications like Diabetic ketoacidosis, retinopathy, Nephropathy, CHD, CVD etc D) Several liver and renal diseases E) Severe systemic illnesses F) Patient who failed to follow up.

Design outcomes

Primary

MeasureTime frame
Improvement in following objective criteria Lipid profile: Serum cholesterol:200-300mg/dl Serum triglycerides:200-300mg/dl Serum HDL: 30-50 mg/dl Serum LDL: 100-150 mg/dl Serum VLDL: 30-50 mg/dl BMI: 25-30kg/m2Timepoint: Three months with fortnightly follow-up

Secondary

MeasureTime frame
Improvement in subjective criteria such as Dyspea Xanthoma Xanthelasma Corneal arcus Timepoint: Three months with fortnighly follwup

Countries

India

Contacts

Public ContactSayeedur Rahman

Ajmal khan Tibbiya college Aligarh Muslim university Aligarh

drmursaleen@gmail.com9412562724

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026